Turbine raised $25M in a Series B round announced on February 25, 2026. Turbine's platform understands the inner mechanisms of cancer enabling the discovery of novel targets & precision medicinal therapies.
Turbine's platform understands the inner mechanisms of cancer enabling the discovery of novel targets & precision medicinal therapies.
Turbine, based in Budapest, Hungary, announced $25M in Series B financing on February 25, 2026.
Participants include Beiersdorf Venture Capital, Interactive Venture Partners.
the company behind NEUROMARK, a minimally invasive solution to treat chronic rhinitis.
Naboo operates a venue reservation platform adapted to availability and selected criteria.